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Estimates of the global, regional, and national morbidity, 
mortality, and aetiologies of diarrhoea in 195 countries: 
a systematic analysis for the Global Burden of Disease 
Study 2016
GBD 2016 Diarrhoeal Disease Collaborators*
Summary
Background The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2016 provides an up-to-date 
analysis of the burden of diarrhoea in 195 countries. This study assesses cases, deaths, and aetiologies in 1990–2016 
and assesses how the burden of diarrhoea has changed in people of all ages.
Methods We modelled diarrhoea mortality with a Bayesian hierarchical modelling platform that evaluates a wide 
range of covariates and model types on the basis of vital registration and verbal autopsy data. We modelled diarrhoea 
incidence with a compartmental meta-regression tool that enforces an association between incidence and prevalence, 
and relies on scientific literature, population representative surveys, and health-care data. Diarrhoea deaths and 
episodes were attributed to 13 pathogens by use of a counterfactual population attributable fraction approach. 
Diarrhoea risk factors are also based on counterfactual estimates of risk exposure and the association between the risk 
and diarrhoea. Each modelled estimate accounted for uncertainty.
Findings In 2016, diarrhoea was the eighth leading cause of death among all ages (1 655 944 deaths, 95% uncertainty 
interval [UI] 1 244 073–2 366 552) and the fifth leading cause of death among children younger than 5 years 
(446 000 deaths, 390 894–504 613). Rotavirus was the leading aetiology for diarrhoea mortality among children younger 
than 5 years (128 515 deaths, 105 138–155 133) and among all ages (228 047 deaths, 183 526–292 737). Childhood 
wasting (low weight-for-height score), unsafe water, and unsafe sanitation were the leading risk factors for diarrhoea, 
responsible for 80·4% (95% UI 68·2–85·0), 72·1% (34·0–91·4), and 56·4% (49·3–62·7) of diarrhoea deaths in 
children younger than 5 years, respectively. Prevention of wasting in 1762 children (95% UI 1521–2170) could avert 
one death from diarrhoea.
Interpretation Substantial progress has been made globally in reducing the burden of diarrhoeal diseases, driven by 
decreases in several primary risk factors. However, this reduction has not been equal across locations, and burden 
among adults older than 70 years requires attention.
Funding Bill & Melinda Gates Foundation.
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Diarrhoea is a global problem. In 2016, diarrhoea was the 
eighth leading cause of mortality, responsible for more 
than 1·6 million deaths.1 More than a quarter (26·93%) 
of diarrhoeal deaths occurred among children younger 
than 5 years, and about 90% (89·37%) of diarrhoeal 
deaths occurred in south Asia and sub-Saharan Africa.1 
Evidence shows that diarrhoeal diseases dispro- 
portionately affect locations with poor access to health 
care, safe water, and sanitation, and low-income or 
marginalised populations.2 These observations illustrate 
that although challenges exist, diarrhoea mortality is 
largely avoidable and renewed efforts to reduce disease 
burden are urgently needed.
Diarrhoea is present globally among all regions and 
populations. However, an inequitable proportion of 
diarrhoea morbidity and mortality occurs in low-income 
countries, which have fewer resources and less robust 
infrastructure to manage burden than high-income 
countries.3 In recognising the magnitude of this burden, 
the global health community has made prevention and 
treatment of diarrhoeal diseases a priority. For example, 
in 2013, WHO and UNICEF coordinated the Diarrhoea 
and Pneumonia Interventions Study Group that 
developed the Global Action Plan for the Prevention 
and Control of Pneumonia and Diarrhoea and an 
accompanying Lancet Series.4,5 This plan established 
goals to reduce severe incidence and deaths due to 
diarrhoea in children by 2025. Through promoting 
various effective intervention and treatment strategies, 
the Global Action Plan for the Prevention and Cox 
Pneumonia and Diarrhoea targets mortality reductions 
to one in 1000 and reductions in the incidence of severe 
diarrhoea to 75% of the country-specific levels in 2010.
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The Global Burden of Disease, Injuries, and Risk 
Factors Study (GBD) is a systematic, comprehensive, and 
annual effort to quantify the impact of more than 
200 diseases and 80 risk factors.1,6,7 We present an update 
to previously published estimates of diarrhoea morbidity, 
mortality, and risk factors2,8 based on the results in GBD 
2016. We focus on changes to the methodology that have 
improved the precision and accuracy of our estimates, 
and on instances in which our results have diverged 
from previous GBD iterations. Additionally, we discuss 
interventions and treatments that could help to guide 
targeted efforts to reduce diarrhoea burden.
Methods
Overview
The GBD study estimates prevalence, incidence, and 
mortality of diarrhoeal disease by country, age, sex, and 
year. Uncertainty in diarrhoea estimates are maintained 
through the modelling process by use of draws from 
a posterior distribution and is presented as 2·5th and 
97·5th percentiles of the distribution. Detailed methods 
of the GBD study and diarrhoea estimation have been 
previously published.1,2,6,7 Updated flow charts, input data 
for the models, and analytical code are made publicly 
available in compliance with the Guidelines for Accurate 
and Transparent Health Estimates Reporting.9 Detailed 
methodology pertaining specifically to diarrhoea 
estimation is provided in the appendix.
We modelled diarrhoea mortality in the Cause of 
Death Ensemble model (CODEm) platform, which is 
a Bayesian, hierarchical, space–time, ensemble model tool 
(appendix p 4).1,10 CODEm produces a wide variety of 
submodels designed to include a diverse set of covariates 
(eg, safe water and sanitation and childhood under- 
nutrition) and model types (eg, spatiotemporal Gaussian 
process regression and mixed-effects models) to create 
a predictive model for causes of death. A subset (15%) of 
available data are withheld and each submodel is weighted 
on the basis of out-of-sample predictive validity, con- 
tributing proportionally to a final set of 1000 draws. A draw 
is a single realisation from an uncertainty distribution. 
These predictive regression models produce estimates of 
cause-specific mortality based on vital registration, verbal 
autopsy, and surveillance system data. The GBD 2016 cycle 
expanded its data sources by adding 169 country-years of 
vital registration and 24 new verbal autopsy studies, 
including Sample Registration System data for 2004–13 
shared by the Government of India for each state stratified 
by urban or rural residence and for new data from the 
WHO Mortality Database released since GBD 2015.1 We 
added several new covariates for the selection algorithm 
for GBD 2016 including prevalence of childhood wasting 
and underweight, vitamin A deficiency, zinc deficiency, 
health-care access and quality, and safe handwashing. 
A complete list of covariates used in the models can be 
found in the appendix (p 6). A core component of cause of 
death estimation is that the sum of cause-specific mortality 
estimates should be equal to the all-cause mortality 
estimate from the GBD study. This calculation occurs in 
a process called CoDCorrect in which the modelled values 
for diarrhoea are scaled on the basis of the uncertainty of 
those values.1
Research in context
Evidence before this study
Despite substantial improvements in global health, diarrhoeal 
diseases have had a large health impact over the past few 
decades. Since 1990, diarrhoea has been ranked among the top 
ten causes of death and disability-adjusted life-years (DALYs) 
among all ages, and one of the top five causes of death and 
DALYs for children younger than 5 years. Multiple groups 
including the Global Burden of Disease, Injuries, and Risk 
Factors Study (GBD) have measured the burden of diarrhoeal 
diseases, one of the leading causes of morbidity and mortality 
globally. Within the past year, numerous publications have 
described national, regional, and global patterns of disease. 
The GBD 2015 study found that diarrhoeal diseases were the 
ninth leading cause of mortality worldwide in that year, causing 
about 1·31 million deaths (95% uncertainty interval [UI] 
1·23–1·39) among all ages, and disproportionately affecting 
children younger than 5 years (fourth leading cause; 
499 000 deaths, 95% UI 447 000–558 000). Furthermore, in 
2015, an estimated 2·39 billion episodes (95% UI 2·30–2·50) 
of diarrhoeal diseases occurred and an estimated 
71 590 000 episodes (66 443 000–77 206 000) were DALYS 
attributable to diarrhoea.
Added value of this study
This analysis incorporates 290 310 new mortality and 5695 new 
morbidity datapoints from the previous GBD cycle, and has increased 
the granularity of estimates by including 183 new subnational 
locations. This study improves on previous GBD studies by focusing 
on changes in diarrhoea burden from 2015 to 2016, exploring the 
association between case-fatality ratio and Socio-demographic 
Index, providing insight into burden among the youngest and oldest 
age groups, and focusing on quantifiable evidence for the most 
efficient and effective interventions to help guide strategies to target 
risk factors unique to each location.
Implications of all the available evidence
The epidemiology of diarrhoeal disease is changing. Declines in 
mortality, particularly among children younger than 5 years, are 
potentially offset by ageing populations and a growing burden in 
people older than 70 years. Expansion of access to the rotavirus 
vaccine, improvement of child growth and wellbeing, and 
provision of universal access to safe water and sanitation are 
necessary to reduce further the preventable disease burden due 
to diarrhoea.
For the Global Health Data 
Exchange see http://ghdx.
healthdata.org
See Online for appendix
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We modelled diarrhoea incidence in DisMod-MR, 
version 2.1 (DisMod). DisMod is a Bayesian, hierarchical 
meta-regression tool (appendix p 8) that contains 
a compartmental model in which incidence, prevalence, 
and mortality are related in a series of ordinary differential 
equations.6 Input data for these models come from 
scientific literature, population representative surveys, 
and records of hospital and health-care facility use. We 
expanded the database for diarrhoea modelling in the 
2016 cycle to include 139 new sources and 5696 new 
datapoints. As diarrhoea is seasonal in many locations, we 
introduced a method to adjust for data sources that were 
less than a year in duration by fitting a sine-cosine model 
with a period of 6 months for each GBD region and 
adjusting the diarrhoea prevalence on the basis of the 
predicted deviation from the mean (appendix p 9). This 
model includes data from a variety of case definitions and 
DisMod internally estimates an adjustment factor for 
a non-reference definition to the reference definition. The 
reference definition of diarrhoea is three or more 
abnormally loose stools in a 24-h period. We took the 
coefficients of this adjustment for inpatient admission to 
hospital to estimate the number of admissions to hospital 
for diarrhoea at the global level.
The attribution of 13 diarrhoeal aetiologies, identified 
as those significantly associated with moderate-to-severe 
diarrhoea in the Global Enteric Multicenter Study, was 
estimated separately from mortality and morbidity. The 
majority of diarrhoeal aetiologies were attributed with 
a counterfactual approach called a population attributable 
fraction (PAF).2 Our approach accounted for pathogen 
co-detection and detection in healthy individuals, and 
does not necessitate a one pathogen to one episode 
association. PAF is defined as the product of the modelled 
proportion of pathogen detection in diarrhoea samples 
based on a molecular diagnostic case definition and the 
odds ratio (OR) of diarrhoea given the detection of 
a pathogen: 11
ORs are based on molecular diagnostic results from 
the Global Enteric Multicenter Study.12,13 By contrast 
with previous rounds of GBD that followed the Global 
Enteric Multicenter Study age groups, for GBD 2016, 
we defined ORs for children younger than 1 year and all 
age groups older than 1 year. This approach makes 
these ORs consistent with the GBD age groups and 
adds power to the ORs of 1–5 years that are applied to 
all age groups older than 5 years. The proportion 
estimates are from DisMod models and their input data 
from scientific literature and modelled for each age, 
sex, year, and location. The input data for these models, 
including meta-data about the sources, age groups, and 
types of diagnostics, are provided in the appendix 
(pp 3–37). The number of episodes and deaths 
attributable to each aetiology is the product of the total 
number of diarrhoea episodes and deaths, and the PAF 
for that aetiology.
Risk factor attribution and decomposition
Risk factors for diarrhoeal diseases were modelled 
independently with a comparative risk assessment 
framework. Detailed descriptions have been published 
elsewhere.7 Like the diarrhoeal aetiologies, risk factors 
are modelled assuming a counterfactual population. The 
exposure level in a population for a given risk factor was 
modelled with DisMod-MR and spatiotemporal Gaussian 
process regression, depending on the risk factor. Relative 
risks for diarrhoea by risk factor and at each exposure 
level were assessed, usually from published meta-
analyses.
To assess the efficiency of targeted interventions for 
each risk factor, we took advantage of the counterfactual 
definition of risk factor burden, such that the diarrhoea 
mortality rate due to each risk factor is equivalent to the 
reduction expected given complete absence of the risk 
factor. The number needed to treat is an epidemiological 
concept for which the rate of disease in two populations 
is compared and is defined as:14
Attributable risk reduction is defined as the difference 
in the rates between two populations. Because the 
counterfactual rate of disease is the difference between 
diarrhoea mortality rate and mortality rate due to the risk 
factor, the number needed to treat is the inverse of 
diarrhoea mortality rate due to that risk factor.
To determine the contribution of the leading ten risk 
factors for diarrhoea on the overall change in diarrhoea 
mortality rate among children younger than 5 years 
between 2000 and 2016, we used a combinatorial 
process to determine the relative contribution of each 
risk factor to the change in diarrhoea disability-adjusted 
life-years (DALYs).2,8,15 Decomposition for each risk 
factor was done independently and assessed the change 
in diarrhoea mortality due to the risk factor, population 
growth, and population ageing; the remaining change 
was considered part of the unexplained diarrhoea cause 
rate. These analyses are not done at the draw level so 
uncertainty is not propagated through risk factor 
decomposition.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all data in the study and had final responsibility 
for the decision to submit for publication.
PAF = Proportion × 1
OR
1 –
1
Attributable risk reduction
Articles
1214 www.thelancet.com/infection   Vol 18   November 2018
Al
l a
ge
s
Yo
un
ge
r t
ha
n 
5 
ye
ar
s
O
ld
er
 th
an
 7
0 
ye
ar
s
De
at
hs
 
(9
5%
 U
I)
De
at
hs
 p
er
 
10
0 
00
0 
(9
5%
 U
I)
Ep
iso
de
s 
(9
5%
 U
I)
Ep
iso
de
s p
er
 
pe
rs
on
-y
ea
r 
(9
5%
 U
I)
De
at
hs
 
(9
5%
 U
I)
De
at
hs
 p
er
 
10
0 
00
0 
(9
5%
 U
I)
Ep
iso
de
s 
(9
5%
 U
I)
Ep
iso
de
s p
er
 
pe
rs
on
-y
ea
r 
(9
5%
 U
I)
De
at
hs
 
(9
5%
 U
I)
De
at
hs
 p
er
 
10
0 
00
0 
(9
5%
 U
I)
Ep
iso
de
s 
(9
5%
 U
I)
Ep
iso
de
s p
er
 
pe
rs
on
-y
ea
r 
(9
5%
 U
I)
Gl
ob
al
1 6
55
 9
44
 
(1
 24
4 
07
3–
2 3
66
 55
2)
22
·4
 
(1
6·
8–
32
·0
)
4 
48
0 4
00
 6
03
 
(4
 24
6 
99
7 3
96
–
4 
73
7 7
69
 15
9)
0·
61
 
(0
·5
7–
0·
64
)
44
6 0
00
 
(3
90
 89
4–
50
4 6
13
)
70
·6
 
(6
1·
9–
79
·8
)
1 1
05
 4
06
 8
65
 
(9
61
 59
5 6
10
–
1 2
74
 76
7 3
00
)
1·
75
 
(1
·5
2–
2·
02
)
69
4 
01
0 
(4
61
 11
8–
1 0
65
 4
09
)
17
1·
7 
(1
14
·1
–2
63
·5
)
36
4 
92
9 
49
5 
(3
31
 9
40
 37
8–
40
3 1
63
 6
23
)
0·
90
 
(0
·8
2–
1·
00
)
Hi
gh
 in
co
m
e
31
 26
7 
(2
9 
97
0–
32
 74
2)
2·
9 
(2
·8
–3
·1
)
14
1 6
26
 74
1 
(1
33
 50
6 
53
9–
15
0 1
42
 9
71
)
0·
13
 
(0
·1
3–
0·
14
)
76
1 
(6
93
–8
39
)
1·
3 
(1
·2
–1
·5
)
33
 38
8 
92
3 
(2
7 8
29
 6
13
–
40
 6
06
 21
4)
0·
58
 
(0
·4
8–
0·
70
)
26
 9
09
 
(2
5 6
88
–
28
 31
3)
20
·1
 
(1
9·
2–
21
·2
)
22
 6
01
 58
2 
(2
1 0
31
 9
17
–
24
 28
4 
70
3)
0·
17
 
(0
·1
6–
0·
18
)
Hi
gh
-in
co
m
e 
N
or
th
 A
m
er
ica
10
 9
19
 
(1
0 5
06
–
11
 34
5)
3·
0 
(2
·9
–3
·2
)
48
 9
21
 9
76
 
(4
6 
53
3 6
01
–
51
 53
2 6
21
)
0·
14
 
(0
·1
3–
0·
14
)
39
4 
(3
52
–4
40
)
1·
8 
(1
·6
–2
·0
)
9 
05
6 
70
9 
(7
 76
3 9
65
–
10
 6
72
 39
9)
0·
42
 
(0
·3
6–
0·
49
)
8  
74
0 
(8
35
9–
91
11
)
24
·5
 
(2
3·
4–
25
·5
)
4 
02
3 4
11
 
(3
 74
6 
71
0–
4 
31
7 0
44
)
0·
11
 
(0
·1
0–
0·
12
)
Au
st
ra
las
ia
32
2 
(2
91
–3
55
)
1·
1 
(1
·0
–1
·2
)
2 1
66
 11
6 
(2
 03
1 2
89
–
2 3
11
 17
8)
0·
08
 
(0
·0
7–
0·
08
)
12
 
(9
–1
5)
0·
7 
(0
·5
–0
·9
)
23
4 
46
8 
(1
89
 9
96
–
29
0 6
29
)
0·
13
 
(0
·1
1–
0·
16
)
27
6 
(2
45
–3
08
)
9·
7 
(8
·6
–1
0·
8)
23
1  9
51
 
(2
11
 9
32
–
25
2 1
35
)
0·
08
 
(0
·0
7–
0·
09
)
Hi
gh
-in
co
m
e A
sia
 
Pa
cifi
c
41
26
 
(3
56
7–
51
37
)
2·
3 
(2
·0
–2
·8
)
9  
85
8 
03
0 
(9
 30
8 
37
5–
10
 4
55
 51
2)
0·
05
 
(0
·0
5–
0·
06
)
60
 
(5
1–
68
)
0·
8 
(0
·7
–0
·9
)
1 4
67
 32
6 
(1
 20
7 5
65
–
1 7
89
 58
5)
0·
20
 
(0
·1
6–
0·
24
)
3 6
25
 
(3
14
5–
44
72
)
12
·2
 
(1
0·
6–
15
·0
)
2 0
00
 71
8 
(1
 8
47
 4
76
–
2 1
73
 12
9)
0·
07
 
(0
·0
6–
0·
07
)
W
es
te
rn
 Eu
ro
pe
14
 6
86
 
(1
3 8
41
–
15
 54
0)
3·
4 
(3
·2
–3
·6
)
65
 4
08
 59
8 
(6
1 2
99
 34
8–
69
 8
72
 05
5)
0·
15
 
(0
·1
4–
0·
16
)
15
2 
(1
31
–1
76
)
0·
7 
(0
·6
–0
·8
)
16
 6
00
 09
0 
(1
3 5
53
 8
33
–
20
 59
8 
00
3)
0·
76
 
(0
·6
2–
0·
94
)
13
 4
05
 
(1
2 6
15
–
14
 25
8)
22
·3
 
(2
1·
0–
23
·7
)
15
 53
9 
96
7 
(1
4 
44
2 0
61
–
16
 73
1 7
94
)
0·
26
 
(0
·2
4–
0·
28
)
So
ut
he
rn
 La
tin
 A
m
er
ica
12
14
 
(1
10
5–
13
29
)
1·
9 
(1
·7
–2
·0
)
15
 27
2 0
23
 
(1
3  9
90
 39
2–
16
 6
98
 8
62
)
0·
23
 
(0
·2
1–
0·
26
)
14
4 
(1
13
–1
84
)
2·
9 
(2
·2
–3
·7
)
6 
03
0 3
31
 
(4
 9
29
 13
0–
7  3
65
 56
7)
1·
20
 
(0
·9
8–
1·
47
)
86
2 
(7
70
–9
65
)
17
·1
 
(1
5·
3–
19
·1
)
80
5 5
35
 
(7
44
 22
2–
87
8 
02
9)
0·
16
 
(0
·1
5–
0·
17
)
Ce
nt
ra
l E
ur
op
e,
 ea
st
er
n 
Eu
ro
pe
, a
nd
 ce
nt
ra
l A
sia
33
72
 
(2
80
8–
4 
47
)
0·
8 
(0
·7
–1
·0
)
16
3 5
43
 10
8 
(1
54
 18
9 
37
3–
17
4  
37
9 
70
8)
0·
39
 
(0
·3
7–
0·
42
)
1 9
43
 
(1
 41
1–
2 7
16
)
6·
9 
(5
·0
–9
·6
)
50
 8
78
 8
49
 
(4
3  9
57
 06
0–
58
 8
95
 9
77
)
1·
80
 
(1
·5
6–
2·
09
)
77
7 
(7
00
–8
66
)
2·
1 
(1
·9
–2
·3
)
15
 9
64
 72
4 
(1
4  
40
5 4
34
–
17
 72
1 6
28
)
0·
43
 
(0
·3
9–
0·
48
)
Ea
st
er
n 
Eu
ro
pe
55
0 
(4
56
–6
55
)
0·
3 
(0
·2
–0
·3
)
79
 9
11
 70
4 
(7
5 3
79
 53
3–
85
 15
8 
22
6)
0·
38
 
(0
·3
6–
0·
40
)
18
0 
(1
29
–2
46
)
1·
4 
(1
·0
–1
·9
)
23
 6
61
 8
09
 
(2
0  8
48
 51
2–
27
 18
4 
31
6)
1·
83
 
(1
·6
1–
2·
10
)
16
6 
(1
34
–2
07
)
0·
8 
(0
·6
–1
·0
)
7 8
83
 08
3 
(6
 9
83
 4
15
–
8 
84
4 
99
7)
0·
38
 
(0
·3
4–
0·
43
)
Ce
nt
ra
l E
ur
op
e
78
5 
(7
13
–8
57
)
0·
7 
(0
·6
–0
·7
)
47
 6
22
 4
87
 
(4
4 
63
3 2
08
–
50
 8
45
 6
30
)
0·
41
 
(0
·3
9–
0·
44
)
73
 
(6
0–
88
)
1·
3 
(1
·1
–1
·6
)
14
 19
5 4
27
 
(1
1 9
76
 77
7–
17
 02
6 
63
4)
2·
54
 
(2
·1
4–
3·
05
)
54
8 
(4
94
–6
08
)
4·
2 
(3
·8
–4
·7
)
7 0
11
 01
5 
(6
 4
23
 08
9–
7 7
05
 4
60
)
0·
54
 
(0
·5
0–
0·
60
)
Ce
nt
ra
l A
sia
2 0
37
 
(1
 4
96
–
2  8
06
)
2·
3 
(1
·7
–3
·2
)
36
 00
8 
91
7 
(3
3  3
78
 39
7–
39
 08
9 
55
1)
0·
41
 
(0
·3
8–
0·
44
)
1 6
90
 
(1
 17
1–
2 4
54
)
17
·5
 
(1
2·
1–
25
·4
)
13
 02
1 6
13
 
(1
1  0
21
 8
48
–
15
 4
25
 9
71
)
1·
35
 
(1
·1
4–
1·
60
)
64
 
(4
4–
87
)
1·
9 
(1
·3
–2
·6
)
1 0
70
 6
26
 
(9
54
 8
34
–
1  1
93
 36
7)
0·
32
 
(0
·2
9–
0·
36
)
La
tin
 A
m
er
ica
 an
d 
Ca
rib
be
an
24
 02
6 
(2
1  7
16
–
27
 9
07
)
4·
2 
(3
·8
–4
·8
)
45
5 0
80
 8
17
 
(4
30
 79
5 1
66
–
48
1  2
38
 6
63
)
0·
79
 
(0
·7
5–
0·
83
)
8 
82
8 
(7
 58
9–
10
 52
2)
17
·8
 
(1
5·
3–
21
·2
)
14
0 0
34
 4
94
 
(1
23
 8
96
 6
75
–
15
7 5
23
 72
0)
2·
82
 
(2
·5
0–
3·
18
)
8 
83
0 
(7
88
5–
10
 71
5)
32
·1
 
(2
8·
6–
38
·9
)
44
 36
9 
10
9 
(4
1 3
55
 00
8–
47
 9
85
 25
7)
1·
61
 
(1
·5
0–
1·
74
)
Ce
nt
ra
l L
at
in
 A
m
er
ica
10
 6
03
 
(9
82
7–
11
 6
51
)
4·
2 
(3
·9
–4
·6
)
14
5 5
41
 71
3 
(1
36
 22
0 6
54
–
15
5 3
09
 57
1)
0·
57
 
(0
·5
4–
0·
61
)
3 5
52
 
(3
 15
4–
4 
09
3)
15
·6
 
(1
3·
8–
17
·9
)
42
 74
5 8
77
 
(3
7 0
76
 6
69
–
49
 8
51
 78
1)
1·
87
 
(1
·6
2–
2·
18
)
39
04
 
(3
55
3–
44
26
)
35
·6
 
(3
2·
4–
40
·4
)
11
 21
6 
11
9 
(1
0  3
66
 9
13
–
12
 20
6 
83
3)
1·
02
 
(0
·9
5–
1·
11
)
An
de
an
 La
tin
 A
m
er
ica
1 8
98
 
(1
 38
7–
2 8
73
)
3·
2 
(2
·3
–4
·8
)
51
 8
49
 09
6 
(4
8 
72
8 
29
6–
55
 05
9 
13
7)
0·
87
 
(0
·8
1–
0·
92
)
73
3 
(5
54
–9
50
)
11
·0
 
(8
·3
–1
4·
3)
15
 4
37
 4
92
 
(1
3  3
22
 6
54
–
17
 6
16
 6
48
)
2·
32
 
(2
·0
0–
2·
64
)
66
2 
(3
95
–1
 16
8)
24
·7
 
(1
4·
8–
43
·7
)
4 
72
2 6
73
 
(4
 32
1 2
25
–
5  1
83
 6
37
)
1·
76
 
(1
·6
1–
1·
94
)
Ca
rib
be
an
51
35
 
(3
56
8–
74
76
)
11
·2
 
(7
·8
–1
6·
3)
34
 9
76
 74
0 
(3
3  0
08
 6
00
–
37
 09
0 9
31
)
0·
76
 
(0
·7
2–
0·
81
)
2 7
73
 
(1
 72
4–
4 
44
0)
69
·5
 
(4
3·
2–
11
1·
3)
9 
15
9 
74
1 
(7
 9
15
 57
2–
10
 57
5 9
56
)
2·
30
 
(1
·9
8–
2·
65
)
11
80
 
(7
17
–2
00
1)
41
·1
 
(2
5·
0–
69
·8
)
4 
15
0 5
25
 
(3
 8
10
 57
2–
4 
56
3 3
91
)
1·
45
 
(1
·3
3–
1·
59
)
Tr
op
ica
l L
at
in
 A
m
er
ica
61
96
 
(5
91
1–
65
44
)
2·
9 
(2
·7
–3
·0
)
22
2  7
13
 26
8 
(2
11
 37
4 
72
2–
23
4 
91
3 9
99
)
1·
03
 
(0
·9
8–
1·
09
)
1 6
86
 
(1
 4
85
–1
 9
27
)
10
·5
 
(9
·2
–1
2·
0)
72
 6
91
 38
4 
(6
5 2
57
 02
1–
80
 12
3 6
32
)
4·
51
 
(4
·0
5–
4·
97
)
3 0
26
 
(2
87
0–
31
89
)
27
·4
 
(2
6·
0–
28
·9
)
24
 27
9 
79
3 
(2
2 6
31
 8
08
–
26
 09
4 
23
1)
2·
20
 
(2
·0
5–
2·
37
)
(T
ab
le
 1
 co
nt
in
ue
s o
n 
ne
xt
 p
ag
e)
Articles
www.thelancet.com/infection   Vol 18   November 2018 1215
Al
l a
ge
s
Yo
un
ge
r t
ha
n 
5 
ye
ar
s
O
ld
er
 th
an
 7
0 
ye
ar
s
De
at
hs
 
(9
5%
 U
I)
De
at
hs
 p
er
 
10
0 
00
0 
(9
5%
 U
I)
Ep
iso
de
s 
(9
5%
 U
I)
Ep
iso
de
s p
er
 
pe
rs
on
-y
ea
r 
(9
5%
 U
I)
De
at
hs
 
(9
5%
 U
I) 
De
at
hs
 p
er
 
10
0 
00
0 
(9
5%
 U
I)
Ep
iso
de
s (
95
%
 
UI
)
Ep
iso
de
s 
pe
r p
er
so
n-
ye
ar
 (9
5%
 
UI
)
De
at
hs
 
(9
5%
 U
I)
De
at
hs
 p
er
 
10
0 
00
0 
(9
5%
 
UI
)
Ep
iso
de
s (
95
%
 
UI
)
Ep
iso
de
s p
er
 
pe
rs
on
-y
ea
r 
(9
5%
 U
I)
(C
on
tin
ue
d 
fro
m
 p
re
vi
ou
s p
ag
e)
So
ut
he
as
t A
sia
, E
as
t A
sia
, 
an
d 
Oc
ea
ni
a
82
 39
1 
(5
2 8
49
–
11
4 
89
0)
4·
0 
(2
·5
–5
·5
)
77
7  3
67
 10
5 
(7
32
 38
0 1
42
–
82
6 
21
4 
23
6)
0·
37
 
(0
·3
5–
0·
40
)
15
 4
43
 
(1
3 2
67
–
18
 20
8)
12
·5
 
(1
0·
8–
14
·8
)
12
8 
87
9 
19
3 
(1
08
 56
4 
72
7–
15
4 
16
5 6
55
)
1·
05
 
(0
·8
8–
1·
25
)
38
 4
25
 
(1
9 
34
1–
56
 9
71
)
34
·1
 
(1
7·
2–
50
·6
)
57
 14
1 1
06
 
(5
1 3
64
 52
8–
63
 75
5 3
85
)
0·
51
 
(0
·4
6–
0·
57
)
Ea
st
 A
sia
64
43
 
(4
66
8–
10
 21
5)
0·
5 
(0
·3
–0
·7
)
29
2 8
51
 9
84
 
(2
73
 8
45
 01
0–
31
3 0
93
 8
01
)
0·
21
 
(0
·1
9–
0·
22
)
1  9
88
 
(1
 57
3–
2 5
96
)
3·
1 
(2
·4
–4
·0
)
35
 27
6 
46
6 
(2
9 
29
5 0
04
–
43
 25
9 
23
5)
0·
55
 
(0
·4
5–
0·
67
)
2 3
51
 
(1
41
5–
44
40
)
2·
7 
(1
·6
–5
·1
)
24
 6
36
 29
5 
(2
1 8
86
 21
6–
27
 8
07
 6
35
)
0·
28
 
(0
·2
5–
0·
32
)
So
ut
he
as
t A
sia
73
 4
84
 
(4
6 
19
5–
10
1 1
56
)
11
·2
 
(7
·1
–1
5·
4)
47
1 2
72
 77
3 
(4
44
 25
2 3
20
–
49
9 
80
7 3
73
)
0·
72
 
(0
·6
8–
0·
76
)
13
 02
7 
(1
0 9
99
–
15
 52
6)
22
·8
 
(1
9·
3–
27
·2
)
91
 01
3 3
37
 
(7
6 
83
1 3
18
–
10
8 
31
5 2
97
)
1·
60
 
(1
·3
5–
1·
90
)
35
 06
3 
(1
7 3
23
–
53
 56
6)
14
0·
7 
(6
9·
5–
21
4·
9)
31
 9
04
 75
4 
(2
8 
86
4 
52
4–
35
 4
11
 36
7)
1·
28
 
(1
·1
6–
1·
42
)
Oc
ea
ni
a
23
12
 
(1
37
8–
35
91
)
20
·6
 
(1
2·
3–
32
·0
)
13
 24
2 3
48
 
(1
2 4
09
 31
2–
14
 16
3 4
14
)
1·
18
 
(1
·1
1–
1·
26
)
41
4 
(2
24
–7
25
)
29
·3
 
(1
5·
9–
51
·3
)
2 5
89
 39
0 
(2
 16
7 4
09
–
3 1
13
 58
2)
1·
83
 
(1
·5
3–
2·
20
)
91
4 
(4
92
–1
 6
05
)
36
6·
8 
(1
97
·5
–6
43
·7
)
60
0  0
57
 
(5
36
 23
2–
67
4 
46
9)
2·
41
 
(2
·1
5–
2·
71
)
N
or
th
 A
fri
ca
 an
d 
M
id
dl
e E
as
t
34
 9
98
 
(2
6 
76
8–
44
 6
82
)
6·
1 
(4
·7
–7
·8
)
42
6 
33
4 
31
1 
(3
96
 20
5 3
57
–
45
7 6
91
 8
71
)
0·
74
 
(0
·6
9–
0·
80
)
26
 37
3 
(1
9 
53
9–
34
 8
18
)
41
·7
 
(3
0·
9–
55
·1
)
15
2 8
31
 9
44
 
(1
31
 12
4 
30
8–
17
6 
49
5 1
44
)
2·
42
 
(2
·0
8–
2·
79
)
47
51
 
(2
70
8–
92
56
)
26
·9
 
(1
5·
4–
52
·5
)
15
 79
4 
11
8 
(1
4 
30
2 5
10
–
17
 51
8 
84
1)
0·
90
 
(0
·8
1–
0·
99
)
So
ut
h 
As
ia
87
3 8
65
 
(6
05
 18
4–
1 3
56
 35
9)
51
·4
 
(3
5·
6–
79
·8
)
1 4
87
 50
6 
72
8 
(1
 4
08
 02
6 
88
2–
1  5
68
 11
0 8
57
)
0·
88
 
(0
·8
3–
0·
92
)
10
1 9
27
 
(8
5 8
17
–
12
2 1
00
)
66
·4
 
(5
5·
9–
79
·5
)
22
8  
15
8 
06
9 
(1
98
 9
16
 16
7–
26
3  8
37
 05
4)
1·
49
 
(1
·2
9–
1·
72
)
50
8 
45
5 
(3
37
 37
4–
79
8  
29
0)
87
7·
4 
(5
82
·2
–1
 37
7·
5)
17
3 7
02
 6
23
 
(1
56
 34
4 
87
1–
19
3 5
83
 8
14
)
3·
00
 
(2
·7
0–
3·
34
)
Su
b-
Sa
ha
ra
n 
Af
ric
a
60
6 
02
4 
(4
69
 70
7–
79
8  
31
4)
61
·8
 
(4
7·
9–
81
·5
)
1 0
28
 9
41
 79
3 
(9
66
 50
1 1
98
–
1 0
98
 08
9 
85
3)
1·
05
 
(0
·9
9–
1·
12
)
29
0 7
24
 
(2
43
 54
5–
34
2 5
57
)
18
5·
7 
(1
55
·5
–2
18
·8
)
37
1 2
35
 39
3 
(3
22
 15
9 
66
2–
42
8  
79
0 7
76
)
2·
37
 
(2
·0
6–
2·
74
)
10
5 8
63
 
(6
3  4
87
–
16
6 
06
8)
58
9·
3 
(3
53
·4
–9
24
·4
)
35
 35
6 
23
2 
(3
1 9
83
 29
6–
39
 00
6 
42
6)
1·
97
 
(1
·7
8–
2·
17
)
So
ut
he
rn
 
su
b-
Sa
ha
ra
n 
Af
ric
a
24
 9
52
 
(1
8 
13
0–
33
 76
5)
32
·4
 
(2
3·
6–
43
·9
)
80
 17
7 3
23
 
(7
6  
93
9 
91
2–
83
 73
9 
08
7)
1·
04
 
(1
·0
0–
1·
09
)
10
 28
1 
(8
 27
0–
12
 6
96
)
11
9·
4 
(9
6·
1–
14
7·
5)
17
 53
9 
77
3 
(1
5 5
79
 6
77
–
19
 9
64
 9
90
)
2·
04
 
(1
·8
1–
2·
32
)
5 6
36
 
(3
 07
6–
9 
35
4)
23
0·
3 
(1
25
·7
–3
82
·2
)
4 
57
8 
63
7 
(4
 29
2 1
57
–
4 
90
4 
91
1)
1·
87
 
(1
·7
5–
2·
00
)
W
es
te
rn
 su
b-
Sa
ha
ra
n 
Af
ric
a
27
0 0
82
 
(2
13
 6
48
–
33
9  
53
5)
67
·8
 
(5
3·
6–
85
·3
)
38
0 5
66
 26
0 
(3
56
 05
8 
64
9–
40
7 7
06
 30
3)
0·
96
 
(0
·8
9–
1·
02
)
17
7 2
62
 
(1
39
 71
2–
22
0 5
46
)
27
4·
3 
(2
16
·2
–3
41
·3
)
15
7 1
33
 4
99
 
(1
38
 02
7 2
36
–
18
0  7
16
 04
1)
2·
43
 
(2
·1
4–
2·
80
)
28
 6
41
 
(1
6  
79
9–
48
 4
88
)
45
4·
0 
(2
66
·3
–7
68
·6
)
11
 29
3 7
66
 
(1
0 0
62
 6
54
–
12
 57
1 3
63
)
1·
79
 
(1
·6
0–
1·
99
)
Ea
st
er
n 
su
b-
Sa
ha
ra
n 
Af
ric
a
24
2 2
17
 
(1
74
 6
68
–
33
0  0
16
)
62
·6
 
(4
5·
1–
85
·3
)
42
5 9
72
 73
8 
(3
99
 18
3 9
13
–
45
4 
18
0 6
16
)
1·
10
 
(1
·0
3–
1·
17
)
72
 8
36
 
(6
0  1
86
–
85
 26
0)
11
6·
4 
(9
6·
2–
13
6·
3)
13
7 2
66
 73
4 
(1
18
 57
3 2
09
–
15
9 
01
7 5
10
)
2·
19
 
(1
·9
0–
2·
54
)
58
 01
3 
(3
5 1
54
–
91
 28
3)
80
7·
3 
(4
89
·2
–
1 2
70
·3
)
15
 21
7 0
20
 
(1
3 6
85
 08
4–
16
 8
34
 02
7)
2·
12
 
(1
·9
0–
2·
34
)
Ce
nt
ra
l s
ub
-S
ah
ar
an
 
Af
ric
a
68
 59
9 
(5
0 1
48
–
93
 55
6)
58
·2
 
(4
2·
6–
79
·4
)
14
2 2
25
 4
73
 
(1
31
 30
7 5
39
–
15
4 
05
4 
35
2)
1·
21
 
(1
·1
1–
1·
31
)
30
 30
6 
(2
0 5
36
–
43
 76
7)
14
5·
7 
(9
8·
8–
21
0·
5)
59
 29
5 3
86
 
(5
0  0
47
 39
6–
69
 4
10
 19
3)
2·
85
 
(2
·4
1–
3·
34
)
13
 51
3 
(8
 38
8–
22
 32
6)
66
7·
7 
(4
14
·5
–1
 10
3·
2)
4 
26
6 
80
9 
(3
 8
11
 9
21
–
4  
75
6 
95
5)
2·
11
 
(1
·8
8–
2·
35
)
UI
=u
nc
er
ta
in
ty
 in
te
rv
al
. 
Ta
bl
e 1
: E
pi
so
de
s a
nd
 d
ea
th
s a
m
on
g 
al
l a
ge
s,
 ch
ild
re
n 
yo
un
ge
r t
ha
n 
5 
ye
ar
s,
 a
nd
 a
du
lt
s o
ld
er
 th
an
 7
0 
ye
ar
s,
 in
 2
01
6,
 b
y 
Gl
ob
al
 B
ur
de
n 
of
 D
is
ea
se
 re
gi
on
s a
nd
 su
pe
r-
re
gi
on
s
Articles
1216 www.thelancet.com/infection   Vol 18   November 2018
(Figure 1 continues on next page)
Articles
www.thelancet.com/infection   Vol 18   November 2018 1217
Results
We estimated that in 2016, diarrhoea was the eighth 
leading cause of death among all ages (1 655 944 deaths, 
95% UI 1 244 073–2 366 552; table 1) and the fifth leading 
cause of death among children younger than 5 years 
(446 000 deaths, 390 894–504 613; table 1). Overall, the 
diarrhoea mortality was 22·4 deaths (16·8–32·0) per 
100 000 in 2016 with higher rates among children 
younger than 5 years (70·6 deaths [61·9–79·8] per 
100 000) and among adults older than 70 years 
(171·7 deaths [114·1–263·5] per 100 000; table 1, figure 1). 
The highest rate of diarrhoea mortality among children 
younger than 5 years occurred in Chad (499 deaths 
[345–686] per 100 000), the Central African Republic 
(384·2 deaths [237–596] per 100 000), and Niger 
(376 deaths [234–559] per 100 000; figure 1). Diarrhoea 
was responsible for 8·92% (95% UI 7·95–9·94) of all 
deaths in children younger than 5 years in 2016, with 
a higher share of deaths in girls younger than 5 years 
(9·02%, 7·76–10·47) than in boys of the same age 
(8·84%, 7·58–10·22). Among children younger than 
5 years, we estimated 1 105 406 865 episodes (95% UI 
961 595 610–1 274 767 300) of diarrhoea in 2016 and 
1·75 episodes (1·52–2·02) per child younger than 5 years 
(table 1). Diarrhoea was the third leading cause of DALYs 
in 2016, responsible for 74·4 million DALYs (95% UI 
63·4–93·4), and 40·1 million (63%) of those occurred 
among children younger than 5 years (35·5–45·1 million).
Diarrhoea was the eighth leading cause of mortality 
among adults aged 70 years and older (171·7 deaths 
[95% UI 114·1–263·5] per 100 000), responsible for 
694 010 deaths (461 118–1 065 409) in this age group in 
2016. Diarrhoea mortality among adults older than 
70 years was highest in Kenya (1877 deaths [1184–3029] 
per 100 000), Central African Republic (1282 deaths 
[680–2112] per 100 000), and India (1013 deaths [667–1578] 
per 100 000; figure 1). Similar to diarrhoea among 
children younger than 5 years, mortality among adults 
older than 70 years was greatest in the lowest Socio-
demographic Index (SDI) quantile (773·9 deaths 
[490·3–1241·8] per 100 000) and lowest in the high-
middle quintile of SDI (8·6 deaths [6·4–11·1] per 
100 000). Although the mortality rate in adults older than 
70 years was nearly three times greater than the rate in 
children younger than 5 years, diarrhoea incidence in 
adults older than 70 years was about half that of the 
incidence in children younger than 5 years (0·90 episodes 
[95% UI 0·82–1·00] per person-year).
The number of diarrhoea deaths among children 
younger than 5 years has decreased by 56·5% (95% UI 
Figure 1: Diarrhoea mortality rate in 2016
Diarrhoea mortality rate in individuals of all ages (A), children younger than 5 years (B), and adults older than 70 years (C). U5MR=under-5 mortality rate. ATG=Antigua and Barbuda. VCT=Saint Vincent 
and the Grenadines. LCA=Saint Lucia. TTO=Trinidad and Tobago. Isl=Islands. FSM=Federated States of Micronesia. TLS=Timor-Leste.
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49·5–62·6; from 1 204 538 to 445 600) since 2000, and 
diarrhoea mortality in this age group has decreased by 
59·3% (52·7–65·0; from 173·3 per 100 000 to 70·6 per 
100 000). Diarrhoea incidence among children younger 
than 5 years decreased by 12·7% (10·6–14·8) between 
2000 and 2016 (from 2·0 per child-year to 1·75 per child-
year). Although diarrhoea mortality rate among adults 
older than 70 years has decreased by 31·8% (32·4–43·4) 
since 2000 (from 251·7 per 100 000 to 171·7 per 100 000), 
the number of deaths did not significantly change 
(2·7% increase, –14·8 to 33·3; from 675 843 to 694 010) 
during that time, suggesting that population ageing has 
increased diarrhoea burden in this age group. The 
greatest increase in diarrhoea mortality among adults 
older than 70 years occurred in high-income locations 
(from 7534 deaths to 25 340 deaths) including the USA, 
where mortality increased by 178·0% (171·6–202·1; from 
8·1 per 100 000 to 23·2 per 100 000) between 2000 and 
2016, and the number of deaths in this age group 
increased by 264·8% (245·2–283·9; from 2027 to 7396).
The case-fatality ratio (CFR) of diarrhoea quantifies the 
association between disease incidence and mortality. The 
CFR among children younger than 5 years decreases non-
linearly with SDI, a composite measure of fertility, 
education, and income (figure 2). The highest CFR among 
children younger than 5 years in 2016 occurred in Lesotho 
(0·16%, 95% UI 0·12–0·20%). Other high CFRs occurred 
in western sub-Saharan Africa including Sierra Leone 
(0·15%, 0·12–0·19) and Mali (0·15%, 0·12–0·19; figure 2). 
Countries in southern sub-Saharan Africa, including 
Lesotho, Botswana, and South Africa, had higher CFRs 
than expected based on the SDI alone, perhaps due to the 
high HIV burden in these regions (figure 2). Conversely, 
Palestinian territory had a much lower CFR (<0·001%) 
than expected based on SDI, joined by numerous 
countries in southeast Asia such as Vietnam, Cambodia, 
and Sri Lanka (figure 2). The global CFR among boys 
younger than 5 years (0·042%, 95% UI 0·041–0·042%) 
was also marginally higher than among girls younger than 
5 years (0·039%, 0·038–0·039).
Rotavirus was the leading aetiology for diarrhoea 
mortality among all children younger than 5 years 
(128 515 deaths, 95% UI 105 138–155 133) and among all 
ages (228 047 deaths, 183 526–292 737) at the global level 
(table 2). Among estimated causes, Clostridium difficile 
was responsible for the fewest deaths in children younger 
than 5 years globally (1958 deaths, 1458–2623), but was 
responsible for the most deaths among children younger 
than 5 years (138 deaths, 111–169) and among all ages 
(7761 deaths, 6874–8703) in high SDI countries. Global 
diarrhoea mortality among individuals older than 5 years 
was dominated by shigella. Of the 212 438 deaths 
(136 979–326 913) attributable to shigella in 2016, nearly 
70% occurred in individuals older than 5 years (table 2). 
Vibrio cholerae (cholera) was the third leading cause of 
diarrhoea mortality among all ages, responsible for 
107 290 deaths (66 518–180 436).
Childhood wasting, defined as having a weight-for-
height score more than 2 SDs less than the mean, and 
unsafe water and sanitation were the leading risk 
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Figure 2: Assocation between the Socio-demographic Index and diarrhoea case fatality in children younger 
than 5 years in 2016
Each point represents a country. 
Deaths (95% UI) Deaths per 
100 000 
(95% UI)
Millions of 
episodes 
(95% UI)
Episodes per 
1000 
(95% UI)
Fatal 
attributable 
fraction (95% UI)
Adenovirus
All ages 93 286 
(62 645–136 144)
1·3 
(0·8–1·8)
165·48 
(118·49–222·38)
22·4 
(16·0–30·1)
5·68% 
(4·07–7·71)
Younger than 
5 years
52 613 
(34 709–74 377)
8·3 
(5·5–11·8)
75·27 
(46·93–117·80)
119·1 
(74·3–186·4)
11·78% 
(8·19–16·13)
70 years or 
older
23 872 
(13 596–41 598)
5·9 
(3·4–10·3)
9·47 
(6·30–13·34)
23·4 
(15·6–33·0)
3·43% 
(2·37–4·67)
Aeromonas
All ages 16 881 
(5649–38 788)
0·2 
(0·1–0·5)
39·33 
(17·90–73·78)
5·3 
(2·4–10·0)
1·02% 
(0·34–2·18)
Younger than 
5 years
6332 
(2098–13 192)
1·0 
(0·3–2·1)
16·83 
(6·47–39·14)
26·6 
(10·2–61·9)
1·42% 
(0·47–2·92)
70 years or 
older
7974 
(1812–19 666)
2·0 
(0·4–4·9)
3·88 
(1·49–8·08)
9·6 
(3·7–20·0)
1·14% 
(0·29–2·79)
Amoebiasis
All ages 26 748 
(5826–74 570)
0·4 
(0·1–1·0)
123·50 
(54·69–257·47)
16·7 
(7·4–34·8)
1·62% 
(0·34–4·45)
Younger than 
5 years
4567 
(568–17 863)
0·7 
(0·1–2·8)
21·38 
(4·79–63·92)
33·8 
(7·6–101·2)
1·02% 
(0·13–3·99)
70 years or 
older
9673 
(1566–30 389)
2·4 
(0·4–7·5)
5·65 
(1·97–13·90)
14·0 
(4·9–34·4)
1·40% 
(0·22–4·51)
(Table 2 continues on next page)
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factors for diarrhoea mortality. Childhood wasting was 
responsible for 80·4% (95% UI 68·2–85·0) of diarrhoea 
deaths and the proportion of deaths attributable to 
wasting was unchanged between 2006 and 2016 
(77·2% in 2006 vs 77·0% in 2016). Unsafe water 
(72·1%, 34·0–91·4) and unsafe sanitation (56·4%, 
49·3–62·7) were the second and third leading risk 
factors among children younger than 5 years, 
respectively, and were the first (70·1% [32·2–89·5] of 
diarrhoea deaths) and second (54·2% [47·1–60·4] of 
diarrhoea deaths) leading risks among all ages, 
respectively.
Figure 3 shows ten risk factors for diarrhoea mortality 
among children younger than 5 years and the 
independent decomposition of each on diarrhoea 
mortality between 2000 and 2016. Globally, reduction in 
childhood wasting was responsible for an 11·8% decrease 
in diarrhoea mortality during this time. Decreasing 
wasting prevalence was responsible for the largest 
decrease in diarrhoea mortality in three super-regions, 
with the largest decrease in sub-Saharan Africa (14·3%) 
and the smallest in central Europe, eastern Europe, and 
central Asia (4·3%). Improvements in sanitation were 
responsible for a 15·4% decrease in southeast Asia, 
east Asia, and Oceania, and a greater than 10% decrease 
in diarrhoea mortality globally. The introduction of the 
rotavirus vaccine has contributed to almost a 7% reduction 
in mortality of children younger than 5 years due to 
diarrhoea in the high-income super-region (6·8%) and 
more than 6% in Latin America and the Caribbean 
(6·2%).
By taking the inverse of the under-5 mortality rate in the 
same ten interventions, we estimated the number of 
children treated that could prevent one death. 
Interventions to address childhood wasting require the 
fewest number of children needed to treat to prevent 
a diarrhoea death globally and in every super-region other 
than the high-income super-region. At the global level, 
prevention of wasting in 1762 children (95% UI 1521–2170) 
could avert one death from diarrhoea (figure 4). Although 
interventions to address under- nutrition might be shared 
across growth indicators, we estimated that direct 
intervention on underweight and stunting would not be 
as efficient in the prevention of diarrhoea deaths. 
Provision of access to safe water (1964 children, 1481–4223) 
and use of oral rehydration solution (2490, 1748–4171) are 
globally the second and third most impactful interventions, 
respectively (figure 4). The relative ranking of efficiency 
among risk factors and interventions was similar among 
countries with high and low diarrhoea mortality. Six risk 
factors (childhood wasting, unsafe water, oral rehydration, 
unsafe sanitation, handwashing, and therapeutic zinc) 
need to reach fewer than 3000 children to avert 
one diarrhoea death in sub-Saharan Africa (figure 4). 
Results for GBD 2016, including all models, mortality, 
incidence, and DALYs are published in the Global Health 
Data Exchange.
Discussion
Much progress has been made in the reduction of 
diarrhoea burden among children younger than 5 years; 
however, diarrhoea remains a leading cause of death and 
morbidity. The results of this analysis indicate that 
Deaths (95% UI) Deaths per 
100 000 
(95% UI)
Millions of 
episodes 
(95% UI)
Episodes per 
1000 
(95% UI)
Fatal 
attributable 
fraction (95% UI)
(Continued from previous page)
Campylobacter spp
All ages 75 135 
(44 356–117 056)
1·0 
(0·6–1·6)
172·33 
(115·98–246·71)
23·3 
(15·7–33·4)
4·58% 
(2·73–6·92)
Younger than 
5 years
40 854 
(20 397–65 633)
6·5 
(3·2–10·4)
88·35 
(47·13–162·40)
139·8 
(74·6–257·0)
9·15% 
(4·60–14·62)
70 years or 
older
17 345 
(8166–33 209)
4·3 
(2·0–8·2)
7·63 
(4·54–12·07)
18·9 
(11·2–29·9)
2·50% 
(1·31–4·30)
Vibrio cholerae 
All ages 107 290 
(66 518–180 436)
1·5 
(0·9–2·4)
2·88 
(2·28–4·04)
0·4 
(0·3–0·5)
6·52% 
(4·02–10·02)
Younger than 
5 years
52 232 
(31 017–85 372)
8·3 
(4·9–13·5)
0·90 
(0·64–1·40)
1·4 
(1·0–2·2)
11·71% 
(7·03–18·92)
70 years or 
older
4741 
(1960–10 594)
1·2 
(0·5–2·6)
0·19 
(0·14–0·27)
0·5 
(0·3–0·7)
0·68% 
(0·31–1·23)
Clostridium difficile
All ages 22 417 
(16 946–32 219)
0·3 
(0·2–0·4)
0·18 
(0·16–0·21)
0·0 
(0·0–0·0)
1·36% 
(1·06–1·74)
Younger than 
5 years
1958 
(1458–2623)
0·3 
(0·2–0·4)
0·02 
(0·01–0·02)
0·0 
(0·0–0·0)
0·44% 
(0·33–0·58)
70 years or 
older
8899 
(7105–11 852)
2·2 
(1·8–2·9)
0·07 
(0·05–0·09)
0·2 
(0·1–0·2)
1·31% 
(0·94–1·80)
Cryptosporidium spp
All ages 57 203 
(29 837–94 748)
0·8 
(0·4–1·3)
69·52 
(36·09–118·13)
9·4 
(4·9–16·0)
3·53% 
(1·73–6·24)
Younger than 
5 years
48 301 
(24 612–81 934)
7·6 
(3·9–13·0)
44·84 
(19·99–88·70)
71·0 
(31·6–140·4)
10·83% 
(5·58–17·81)
70 years or 
older
1996 
(683–4559)
0·5 
(0·2–1·1)
0·74 
(0·32–1·34)
1·8 
(0·8–3·3)
0·29% 
(0·11–0·59)
Enteropathogenic Escherichia coli
All ages 12 337 
(4439–25 697)
0·2 
(0·1–0·3)
14·26 
(5·63–30·90)
1·9 
(0·8–4·2)
0·76% 
(0·26–1·62)
Younger than 
5 years
9459 
(2620–20 094)
1·5 
(0·4–3·2)
8·28 
(2·29–23·36)
13·1 
(3·6–37·0)
2·12% 
(0·61–4·60)
70 years or 
older
1464 
(513–3471)
0·4 
(0·1–0·9)
0·37 
(0·16–0·65)
0·9 
(0·4–1·6)
0·21% 
(0·08–0·49)
Enterotoxigenic E coli
All ages 51 186 
(26 757–83 064)
0·7 
(0·4–1·1)
222·64 
(144·95–322·85)
30·1 
(19·6–43·7)
3·10% 
(1·70–4·63)
Younger than 
5 years
18 669 
(9800–30 659)
3·0 
(1·6–4·9)
75·16 
(39·69–130·35)
118·9 
(62·8–206·3)
4·19% 
(2·21–6·85)
70 years or 
older
18 152 
(7957–34 248)
4·5 
(2·0–8·5)
15·00 
(9·09–22·80)
37·1 
(22·5–56·4)
2·61% 
(1·27–4·12)
Norovirus
All ages 19 496 
(8747–38 421)
0·3 
(0·1–0·5)
139·63 
(47·77–278·41)
18·9 
(6·5–37·7)
1·19% 
(0·52–2·36)
Younger than 
5 years
10 629 
(5274–19 582)
1·7 
(0·8–3·1)
48·56 
(19·02–100·87)
76·8 
(30·1–159·6)
2·38% 
(1·22–4·34)
70 years or 
older
3693 
(810–8647)
0·9 
(0·2–2·1)
7·60 
(2·15–16·26)
18·8 
(5·3–40·2)
0·54% 
(0·14–1·27)
(Table 2 continues on next page)
For GBD 2016 results see http://
ghdx.healthdata.org/gbd-2016/
data-input-source
Articles
1220 www.thelancet.com/infection   Vol 18   November 2018
progress in the reduction of diarrhoea mortality is not 
equal across locations and regions, which is in part 
driven by decreases in several primary risk factors, and 
that the burden in elderly adults is an increasing public 
health challenge that requires appropriate attention.
Our results suggest that nearly three-quarters of 
diarrhoea deaths occurred in individuals older than 5 years, 
with a particularly high burden in adults older than 
70 years. Mortality rates in this age group have decreased 
in most regions of the world since 1990 (42% decrease 
globally) and yet, as countries have moved through 
epidemiological transition, the population of adults older 
than 70 years has increased globally. The number of adults 
older than 70 years has increased by 50% from 1990 to 
2016. Much of the global initiative to reduce the diarrhoea 
burden has been focused in children younger than 5 years; 
however, our results suggest that neglect of the burden in 
adults will have increasingly negative consequences. The 
high burden of Clostridium difficile in high-income 
countries, particularly in elderly age groups, might explain 
some of the increasing diarrhoea mortality because this 
bacterium is difficult to treat, is often resistant to 
antibiotics, and is frequently associated with nosocomial 
and retirement home outbreaks.16,17 Further exploration of 
the impact of comorbidities and other risk factors that put 
elderly people at risk of diarrhoea should be investigated.
Although diarrhoea incidence in children younger than 
5 years decreased in most countries during this time, it 
decreased at a slower rate in most locations than the 
mortality rate, and it increased in some countries. This 
finding suggests that the primary drivers of change in 
diarrhoea mortality have been ones that preferentially 
reduce the risk of dying from the disease rather than those 
that reduce the risk of infection. Interventions to prevent 
Deaths (95% UI) Deaths per 
100 000 
(95% UI)
Millions of 
episodes 
(95% UI)
Episodes per 
1000 
(95% UI)
Fatal 
attributable 
fraction (95% UI)
(Continued from previous page)
Non-typhoidal Salmonella spp
All ages 84 799 
(46 201–144 935)
1·1 
(0·6–2·0)
197·35 
(127·37–299·20)
26·7 
(17·2–40·5)
5·17% 
(2·87–8·48)
Younger than 
5 years
37 410 
(16 659–64 509)
5·9 
(2·6–10·2)
64·00 
(31·32–122·03)
101·3 
(49·6–193·1)
8·38% 
(3·88–14·04)
70 years or 
older
19 056 
(8451–35 666)
4·7 
(2·1–8·8)
9·77 
(5·55–16·14)
24·2 
(13·7–39·9)
2·76% 
(1·37–4·70)
Rotavirus
All ages 228 047 
(183 526–292 737)
3·1 
(2·5–4·0)
591·73 
(496·00–695·46)
80·0 
(67·1–94·1)
13·91% 
(11·51–16·34)
Younger than 
5 years
128 515 
(105 138–155 133)
20·3 
(16·6–24·5)
258·20 
(196·95–336·88)
408·6 
(311·6–533·1)
28·78% 
(25·22–32·40)
70 years or 
older
57 594 
(36 869–91 286)
14·2 
(9·1–22·6)
29·03 
(21·92–37·78)
71·8 
(54·2–93·4)
8·31% 
(6·83–9·91)
Shigella
All ages 212 438 
(136 979–326 913)
2·9 
(1·9–4·4)
269·19 
(176·68–369·00)
36·4 
(23·9–49·9)
12·85% 
(9·01–17·09)
Younger than 
5 years
63 713 
(41 191–93 611)
10·1 
(6·5–14·8)
74·77 
(41·40–127·74)
118·3 
(65·5–202·1)
14·28% 
(9·58–20·74)
70 years or 
older
74 402 
(42 443–128 668)
18·4 
(10·5–31·8)
16·39 
(10·46–23·36)
40·5 
(25·9–57·8)
10·73% 
(7·18–14·81)
UI=uncertainty interval.
Table 2: Deaths, attributable fraction, and episodes due to each diarrhoea aetiology among all ages, 
children younger than 5 years, and adults older than 70 years, in 2016 globally
Figure 3: Reduction in under-5 mortality rate due to diarrhoea, 2000–16
–15 –10 –5 0
Lo
ca
tio
n
Change (%)
High income
Central Europe, eastern
Europe, and central Asia
Southeast Asia,
east Asia, and Oceania
North Africa and
Middle East
South Asia
Sub-Saharan Africa
Latin America
and Caribbean
Global
Child wasting
Unsafe sanitation
Low coverage of oral rehydration solution
Risk factor
Unsafe water source
Child underweight
Child stunting
Low coverage of rotavirus vaccine
No access to handwashing facility
Non-exclusive breastfeeding
Low coverage
of zinc 
treatment
Articles
www.thelancet.com/infection   Vol 18   November 2018 1221
Un
saf
e   
 
san
ita
tio
n No
    
ha
nd
wa
sh
ing
Th
era
pe
uti
c   
 
zin
c
No
n-e
xcl
usi
ve
    
bre
ast
fee
din
g
Ro
tav
iru
s   
  
va
cci
ne
Wa
sti
ng
Un
saf
e w
ate
r
Or
al h
yd
rat
ion
Stu
nti
ng
Un
de
rw
eig
ht
Co
un
tr
y
Co
un
tr
y
Risk factor
Afghanistan
Rwanda
Egypt
Mozambique
Sudan
Laos
Comoros
Botswana
Tanzania
India
São Tomé and Príncipe
South Africa
Kiribati
Guatemala
Gabon
Djibouti
Morocco
Suriname
Papua New Guinea
Ghana
Chad
Central African Republic
Niger
Sierra Leone
Mali
Burundi
Lesotho
Nigeria
Liberia
Madagascar
Benin
Côte d’Ivoire
Swaziland
Zimbabwe
Namibia
Haiti
Guinea-Bissau
Angola
Eritrea
Somalia
Un
saf
e   
 
san
ita
tio
n No
    
ha
nd
wa
sh
ing
Th
era
pe
uti
c   
 
zin
c
No
n-e
xcl
usi
ve
    
bre
ast
fee
din
g
Ro
tav
iru
s   
  
va
cci
ne
Wa
sti
ng
Un
saf
e w
ate
r
Or
al h
yd
rat
ion
Stu
nti
ng
Un
de
rw
eig
ht
Risk factor
Indonesia
Honduras
Fiji
Guyana
Myanmar
Kyrgyzstan
Solomon Islands
Panama
Philippines
Nepal
Bolivia
Dominican Republic
Bangladesh
Iraq
North Korea
Vanuatu
Bhutan
Nicaragua
Turkmenistan
Burkina Faso
Senegal
Pakistan
DR Congo
Yemen
Guinea
Cameroon
Timor−Leste
South Sudan
Malawi
The Gambia
Mauritania
Zambia
Ethiopia
Kenya
Uganda
Togo
Congo
Tajikistan
A
C
B
D
(Figure 4 continues on next page)
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diarrhoea mortality should be targeted to the unique 
characteristics of different countries and regions. Our 
estimates regarding the number of children that need to 
be treated to prevent a diarrhoea death facilitate the 
necessary discussion about targeted intervention 
implementation. For example, promotion of a hand-
washing campaign in central Europe, eastern Europe, or 
central Asia would require reaching at least 60 000 more 
individuals than would promotion of intervention 
strategies for wasting, unsafe water, or oral rehydration. 
Conversely, in sub-Saharan Africa, 500–1000 more 
individuals would need to be reached through 
a handwashing campaign than through an intervention 
for wasting, unsafe water, or oral rehydration. Because the 
cost of intervention delivery might vary, and sometimes 
substantially between interventions, the number needed 
to treat could be an important factor in the assessment of 
the cost-effectiveness of such interventions.
Childhood undernutrition, stunting, wasting, and 
underweight were among the leading risks for diarrhoea 
in children younger than 5 years. Numerous reasons 
exist as to why many children in low-income countries, 
born underweight or not, tend to progressively deviate 
from the global age curves as they get older.18 One reason 
might be a positive reinforcement loop that exists 
between infectious disease incidence causing poor 
physical growth, which subsequently predisposes 
children to future episodes of infectious diseases.19–21 In 
fact, diarrhoea burden might be underestimated in 
this analysis.18 Diarrhoea as a comorbidity with other 
infectious causes of death might contribute to mortality 
while not being the underlying cause of death. The GBD 
study assumes that causes of death are mutually exclusive 
and collectively exhaustive, and that each death is 
attributable to a single cause. Disentangling the impact 
of diarrhoea on other causes of death is challenging. 
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Figure 4: Heat map of the number of children younger than 5 years that were needed to treat to prevent a diarrhoea death in 2016
Countries are ordered by the diarrhoea mortality rate among children younger than 5 years into deciles from Chad (highest mortality rate) to Finland (lowest mortality rate).
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Evidence exists to suggest that diarrhoea impairs 
childhood growth,19 and by accounting for the increased 
risk of subsequent infectious disease episodes due to 
growth faltering attributable to diarrhoea, the total 
number of DALYs due to diarrhoea could increase by up 
to 40% globally.18 The breaking of this loop has proved 
challenging but some countries have succeeded more 
than others. Beyond socioeconomic development, this 
success might be due in part to improved maternal 
education, prenatal care, and interventions that target 
mothers and children.22,23 For example, Angola, Mongolia, 
and Vietnam have successfully improved childhood 
nutrition and reduced the burden of diarrhoea.
Our results show that the CFR among children young-
er than 5 years decreases rapidly with increasing 
sociodemographic development. We previously showed 
that diarrhoea mortality decreases much quicker with 
SDI than diarrhoea incidence, suggesting a strong 
association exists between factors that relate to high 
excess mortality due to diarrhoea.2 This trend has 
numerous explanations, including improved access to 
health care and nutrition, and possibly improved case 
management. A key goal of the Global Action Plan for 
the Prevention and Control of Pneumonia and Diarrhoea 
was universal access to oral rehydration solution and 
antibiotic use for dysentery.24 Our results suggest that 
expanded use of oral rehydration solution contributed to 
a decrease in global mortality due to diarrhoea in children 
younger than 5 years between 2000 and 2016 and was the 
second largest individual driver of this change in 
sub-Saharan Africa. Despite modest increases in 
coverage of oral rehydration solution,25 this intervention 
can still prevent up to 30% of diarrhoea deaths 
(about 4000 children need to be reached to prevent one 
diarrhoea death) and expanding its use could be 
inexpensive and effective.26,27
Despite a growing number of countries introducing 
the rotavirus vaccine, many with support from the Gavi 
Alliance,28 our results suggest that rotavirus is by far the 
leading aetiology responsible for diarrhoea incidence and 
mortality in children and adults. We estimated that 
introduction and expanded use of the rotavirus vaccine 
was responsible for a 2·6% decrease in mortality of 
children younger than 5 years due to diarrhoea between 
2000 and 2016, and its use prevented nearly 27 000 deaths 
in 2016. More than 120 000 deaths among children 
younger than 5 years were due to rotavirus, the fifth most 
fatal pathogen globally.1 These findings should spur 
advocacy for improved access to the rotavirus vaccine. 
Shigella was the second leading cause of diarrhoea 
mortality and responsible for a high attributable fraction 
among children younger than 5 years (12·9%) and adults 
older than 70 years (10·7%). In fact, shigella was the 
leading cause of diarrhoea mortality among those older 
than 70 years. Although no efficient and inexpensive 
point-of-care diagnostic exists for diarrhoeal pathogens, 
WHO guidelines recommend that suspected episodes 
of shigella-associated diarrhoea are treated with the 
appropriate antibiotics.29 Several shigella vaccine 
candidates are in development and our results indicate 
that their use could prevent deaths among young and 
elderly populations at risk of death caused by diarrhoea.30,31 
Cholera epidemics continue to inflict a major burden 
globally, particularly in post-disaster and conflict-
devastated locations. Deaths due to cholera are treated as 
a fatal discontinuity, or catastrophic event, in GBD 
studies and are added to the total number of diarrhoea 
deaths after the standard modelling process for mortality. 
This process helps to capture the epidemic nature of the 
disease that our models might otherwise miss or 
statistically smooth over.1
GBD 2016 estimates of diarrhoea mortality in children 
younger than 5 years in 2015 are nearly identical to the 
estimates produced for GBD 2015 in the same year (485 827, 
95% UI 429 412–547 489 vs 498 889, 447 450–557 643)2 and are 
approximately 8% lower than those produced by the WHO 
Department of Evidence, Information and Research and the 
Maternal and Child Epidemiology Estimation group 
(525 977; appendix p 46).32 The appendix shows a comparison 
of aetiologies for diarrhoea-attributable mortality among 
children younger than 5 years by the Child Health 
Epidemiology Research Group, from which the WHO 
Department of Evidence, Information and Research and the 
Maternal and Child Epidemiology Estimation group was 
developed,33 and GBD 2015 estimates for 2010 (p 48). 
A systematic review of community-based studies on 
diarrhoea morbidity found an estimated 3·4 episodes of 
diarrhoea per child-year in 1990, decreasing to 2·9 in 2010; 
these estimates are higher than the GBD 2016 estimates 
(2·1 episodes [95% UI 1·9–2·5] per child-year in 1990, and 
1·9 episodes [1·7–2·2] per child-year in 2010).34 Although 
the study was limited to children younger than 2 years, the 
MAL-ED study found that incidence of community 
diarrhoea ranged from about 0·5 episodes per child-year in 
Brazil to 6·2 episodes per child-year in Pakistan.35 These 
data from MAL-ED were included, along with more than 
30 000 other datapoints on diarrhoea incidence or prevalence 
in GBD 2016 (appendix p 14).
Data availability limits our estimates of diarrhoea 
burden, particularly in regions of the world with the 
greatest mortality and morbidity. The fraction of deaths 
in children younger than 5 years that were well coded 
and the diarrhoea mortality rate in 2016 are inversely 
associated, with a particular absence of data in Africa, 
where an analysis for GBD 2016 found that only Egypt 
had a rating of at least three out of five for completeness 
and coverage.1 Improved surveillance and vital 
registration systems, including standard reporting 
mechanisms and case definitions, in sub-Saharan Africa 
and south and southeast Asia in particular, and additional 
cohort and clinical trials for the impact of interventions, 
would substantially reduce several major sources 
of uncertainty in diarrhoea mortality, aetiological 
attribution, and risk factor estimates.36
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Data on diarrhoea incidence and aetiologies among 
populations older than 5 years are scarce, and studies that 
investigate the role of diarrhoea among adults, particularly 
elderly people, would be valuable. A core GBD principle is 
the inclusion of all reliable data; however, a potential 
consequence is that because of limited data availability, 
certain sources with small sample sizes or that are 
representative of a single site can have large effects on 
estimates. Data scarcity in high burden locations, 
particularly sub-Saharan Africa, result in modelled 
estimates with high uncertainty. For example, inclusion of 
a verbal autopsy study37 in a Nairobi slum had a large 
impact on diarrhoea mortality in Kenyan adults, a study 
that might not be representative of a country without 
many other available cause-of-death data. Furthermore, 
because of a lack of data to calculate ORs for diarrhoea and 
its aetiologies among ages older than 5 years in low-
income and middle-income countries, we have assumed 
that ORs for children aged 1–5 years are the same as for 
older age groups. Although the analysis for these ORs are 
informed by findings from seven countries, it depends on 
a single study and the results could be strengthened with 
additional data from other studies or locations. 
Additionally, ORs tend to be biased away from the null 
compared with risk ratios; therefore, the PAFs used in this 
analysis might overestimate aetiological attribution. We 
assume that aetiologies associated with severe episodes of 
diarrhoea or those that required admission to hospital are 
a proxy for episodes that cause death, an assumption that 
requires confirmation, possibly through vaccine probe 
approaches.
The predictive modelling approaches used in GBD 
2016 rely on covariates and shared information across 
space and time to fill in these data gaps. The risk factors 
described in this analysis are included as covariates in 
the diarrhoea mortality modelling, yet the list of risk 
factors included in this analysis might not be exhaustive; 
evidence on the exposure to food contamination, low 
birthweight, and antibiotic use might improve predictive 
estimates in future analyses. Uncertainty is carried 
through each step of the diarrhoea modelling process 
and is represented in uncertainty intervals for the results. 
A list of all GBD 2016 data sources for each country is 
published in the Global Health Data Exchange.
The GBD study is updated annually. Since a full 
analysis is done on a regular basis, the study is readily 
adaptable to changes in methodology, incorporation of 
new or previously unidentified data sources, and is 
timely with estimates of mortality and morbidity due to 
diarrhoea. Future iterations of GBD studies will benefit 
from strengthened surveillance systems on diarrhoea 
morbidity and mortality, on aetiology burden, particularly 
in adults, and from rigorous intervention evaluations. 
Work to forecast GBD estimates, including diarrhoeal 
diseases up to 2040, will provide a strategic framework 
for investment, and built-in scenarios will allow for the 
evaluation of potential interventions. Work to estimate 
diarrhoea burden at fine spatial resolutions, similar to 
estimates of mortality in children younger than 5 years 
due to malaria,38,39 will provide extremely detailed 
evidence to guide policy at the local level and direct 
interventions to where they could cause the most change. 
This type of public health precision requires strong 
surveillance systems, sophisticated analytical approaches, 
and the capacity to act on the results.40
Although diarrhoeal disease mortality has decreased 
substantially in the past three decades, much work is still 
needed to accelerate the reduction in burden in the 
most vulnerable populations including undernourished 
children, people without reliable access to safe water and 
sanitation, and those without access to appropriate health 
care. We have shown that primary intervention strategies 
to reduce diarrhoea incidence and universal access to the 
rotavirus vaccine and oral rehydration solutions are 
necessary to continue momentum in the improvement 
of diarrhoea burden.
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